Amphastar Pharmaceuticals AMPH Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's operating lease liabilities?
- Amphastar Pharmaceuticals (AMPH) reported operating lease liabilities of $65.2M in Q1 2026.
- How has Amphastar Pharmaceuticals's operating lease liabilities changed year-over-year?
- Amphastar Pharmaceuticals's operating lease liabilities increased by 60.2% year-over-year, from $40.71M to $65.2M.
- What is the long-term trend for Amphastar Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's operating lease liabilities has grown at a 16.6% compound annual growth rate (CAGR), from $17.46M to $37.68M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.